Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J)

BACKGROUND: Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previous reports, we documented 24‐ and 52‐week findings of an open‐label, phase 3 trial (UNCOVER‐J) of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Y., Mabuchi, T., Iwatsuki, K., Elmaraghy, H., Torisu‐Itakura, H., Morisaki, Y., Nakajo, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587497/
https://www.ncbi.nlm.nih.gov/pubmed/30317671
http://dx.doi.org/10.1111/jdv.15287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587497/
https://www.ncbi.nlm.nih.gov/pubmed/30317671
http://dx.doi.org/10.1111/jdv.15287

Ejemplares similares